Cardiol Therapeutics Inc. CRDL.TO
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · cardiolrx.com
Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease. Its lead drug candidate, CardiolRx™, targets the inflammasome pathway and is being evaluated in the pivotal Phase III MAVERIC trial for recurrent pericarditis. The company is dual-listed on the Toronto Stock Exchange and NASDAQ Capital Market and is headquartered in Canada.
Key ratios
ReturnOnAssets TTM -0.77
ReturnOnAssets 2025 -0.77
ReturnOnAssets 2024 -0.73
ReturnOnAssets 2023 -0.38
ReturnOnEquity TTM -1.59
ReturnOnEquity 2025 -1.59
ReturnOnEquity 2024 -1.38
ReturnOnEquity 2023 -0.7
Recent news
Cardiol Therapeutics' Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association
2026-07-14 · CNW
Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders
2026-06-25 · PR Newswire